Eton Pharmaceuticals And Aquestive Therapeutics Enter Exclusive U.S. License And Supply Agreement For LIBERVANT Buccal Film For Seizure Clusters In Patients With Epilepsy; Sees Commercial Availability In April 2027
Benzinga Newsdesk 1 month ago
FDANews
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal and rectal seizure rescue treatments, a market opportunity that exceeds $450 million annually in the U.S.Patient
- Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal and rectal seizure rescue treatments, a market opportunity that exceeds $450 million annually in the U.S.
- Patient market research demonstrated strong preference for buccal film, with 71% of surveyed patients preferring film versus 13% for nasal spray, assuming equivalent efficacy
- Anticipated commercial launch in April 2027, subject to final FDA approval, provides a potential near-term growth opportunity and new commercial platform in neurology
- LIBERVANT has received Orphan Drug Designation and has issued patent protection extending into 2038, with additional patent applications pending with the U.S. Patent and Trademark Office
